abstract |
The invention pertains to compounds that specifically inhibit adenosine A1, A2A and A3 receptors and the use of these compounds to treat a disease associated with adenosine A1, A2A and A3 receptors in an individual, which comprises administering to the individual. a therapeutically effective amount of the compounds. |